from the other side, page-2

here's the full mouse study from Calimmune, which was used to support the human clinical trial now underway. interesting they kept this under wraps until the clinical trial underway.

the sangamo investors seem to be working out, the sangamo approach already in the clinic has a big limitation (doesn't deal with CXCR4 entry, only CCR5), and it appears at least some of their investors have spotted the advantage in the Calimmune approach in being able to deal with this.

Sangamo have benefitted off much publicity of their trial, but this limitation in their approach has been kept pretty quiet.

Sangamo have a programme to deal with the CXCR4 entry but it's nowhere near ready for the clinic.

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0053492